| Bioactivity | Pecavaptan is an orally active and dual antagonist of V1a/V2 receptor (Ki=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema[1]. |
| In Vivo | Pecavaptan (0.01, 0.03, 0.1 and 0.3 mg/kg；静脉注射；单剂量) 在犬心动过速诱发的心力衰竭 (HF) 模型中保护免受精氨酸抗利尿激素 (arginine vasopressin, AVP) 介导的心输出量 (CO) 降低)[1]。 |
| Name | Pecavaptan |
| CAS | 1914998-56-3 |
| Formula | C22H19Cl2F3N6O3 |
| Molar Mass | 543.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mondritzki T, et al. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. Eur J Heart Fail. 2021 May;23(5):743-750. |
Pecavaptan
CAS: 1914998-56-3 F: C22H19Cl2F3N6O3 W: 543.33
Pecavaptan is an orally active and dual antagonist of V1a/V2 receptor (Ki=0.5 nM and 0.6 nM for human, respectively). Pe
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.